Update on progressive supranuclear palsy.
A better understanding of the challenges in the diagnosis of progressive supranuclear palsy (PSP), the most common atypical parkinsonian neurodegenerative disorder, has led to improving its diagnostic accuracy. Similarly, a better understanding of the role of tau mutations, mitochondrial complex I inhibitors, oxidative injury, and inflammation in neurodegeneration has led to an unraveling of potential risk factors for the development of PSP. These advances are explained in detail in this review.
Litvan
Irene
I
Movement Disorder Program, Department of Neurology, University of Louisville School of Medicine, A Building, Room 113, 500 South Preston Street, Louisville, KY 40202, USA. i.litvan@louisville.edu
D000818:Animals; D003952:Diagnostic Imaging / Q000639:trends; D006801:Humans; D013494:Supranuclear Palsy, Progressive / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*